Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst ...
Incyte Corporation (NASDAQ:INCY) reported fourth-quarter revenue of $1.18 billion, up 16% year over year and beating the ...
pharmaphorum2 年
FDA clears Incyte's Opzelura as first vitiligo therapy
Opzelura (ruxolitinib) is now the first alternative to steroid drugs for vitiligo, a chronic autoimmune disease that causes depigmentation of skin and affects around 1.5 million people in the US.